Vaccines for Pregnant Women
Prenatal vaccinations may protect both the mother and the unborn child from infections that can be prevented by antibodies. Due to the fact that their immune systems have not fully developed, newly born children have a higher risk of serious illness and death from several intractable diseases. One goal of immunizing expectant mothers is to increase the amount of maternal counteracting protein (proteins that fight disease) that is transferred to the unborn child, potentially protecting the child from irresistible illness.
- Tdap (Tetanus, Diphtheria and Pertussis) Vaccin
- Influenza (Flu) Vaccine
Related Conference of Vaccines for Pregnant Women
March 24-25, 2026
9th International Conference on Vaccines, Immunology and Clinical Trials
Paris, France
Vaccines for Pregnant Women Conference Speakers
Recommended Sessions
- HIV Vaccines
- Cancer, Malaria & TB Vaccinesv
- Combination & Conjugate Vaccines
- DNA & Synthetic Vaccines
- Human Vaccines Against Infectious Diseases
- New Trends in Vaccines Development
- Pediatric Vaccines
- RDT in Antibiotic Research
- Side-effects of Vaccines
- Toxoid Vaccines
- Vaccine Production & Development
- Vaccine Safety & Efficacy
- Vaccines
- Vaccines for Pregnant Women
- Vaccines for Unconventional Diseases
- Vaccines Manufacturing Technologies
- Vaccines Research and Clinical Trails
- Zika Virus Vaccines
Related Journals
Are you interested in
- Adjuvants and Immunopotentiators - VACCINE CONGRESS 2025 (Japan)
- Adult and Elderly Vaccination Strategies - VACCINE CONGRESS 2025 (Japan)
- Advancements in Vaccine Research and Development - Vaccines R&D 2026 (France)
- Advances in Pediatric Vaccines - Vaccines R&D 2026 (France)
- Adverse reactions to the vaccination - Vaccines Congress-2025 (Canada)
- AI and Data Science in Vaccine Discovery - VACCINE CONGRESS 2025 (Japan)
- Antimicrobial Resistance and Vaccines - VACCINE CONGRESS 2025 (Japan)
- Antinatal vaccinations - Vaccines Congress-2025 (Canada)
- Booster Doses and Heterologous Vaccine Regimens - VACCINE CONGRESS 2025 (Japan)
- Cancer Vaccines and Immunotherapy - VACCINE CONGRESS 2025 (Japan)
- Clinical Trials Design and Methodologies - Vaccines R&D 2026 (France)
- Conjugated and combination vaccinations - Vaccines Congress-2025 (Canada)
- Corporate Innovation, Sponsorship & Exhibition - VACCINE CONGRESS 2025 (Japan)
- COVID-19 Vaccine Impact and Learnings - VACCINE CONGRESS 2025 (Japan)
- Creation and development of vaccines - Vaccines Congress-2025 (Canada)
- DNA, RNA & SYNTHETIC VACCINES - Vaccines Congress-2025 (Canada)
- Emerging Infectious Diseases and Vaccine Development - Vaccines R&D 2026 (France)
- Ethical Considerations in Vaccine Development and Distribution - Vaccines R&D 2026 (France)
- Global Immunization Programs and Policy - VACCINE CONGRESS 2025 (Japan)
- Global Immunization Strategies and Policy - Vaccines R&D 2026 (France)
- HIV , Malaria & TB vaccines - Vaccines Congress-2025 (Canada)
- Immunology of Infectious Diseases - Vaccines R&D 2026 (France)
- Immunotherapy and Personalized Medicine - Vaccines R&D 2026 (France)
- Infectious Disease Vaccines - VACCINE CONGRESS 2025 (Japan)
- Innovations in Vaccine Cold Chain and Storage - Vaccines R&D 2026 (France)
- Manufacturing, Supply Chain, and Distribution - VACCINE CONGRESS 2025 (Japan)
- Nanotechnology in Vaccine Delivery - VACCINE CONGRESS 2025 (Japan)
- Next-Generation Vaccine Technologies - VACCINE CONGRESS 2025 (Japan)
- Pediatric and Neonatal Vaccines - VACCINE CONGRESS 2025 (Japan)
- rDNA technology in vaccine development - Vaccines Congress-2025 (Canada)
- Recent advances in vaccine development - Vaccines Congress-2025 (Canada)
- Regulatory Approaches in Vaccine Development - Vaccines R&D 2026 (France)
- Role of Adjuvants in Vaccine Efficacy - Vaccines R&D 2026 (France)
- Role of AI and Big Data in Vaccine Research - Vaccines R&D 2026 (France)
- The COVID-19 vaccine's next-generation RNA platforms and mRNA - Vaccines Congress-2025 (Canada)
- Toxoid vaccination - Vaccines Congress-2025 (Canada)
- Translational Immunology and Vaccine Development - Vaccines R&D 2026 (France)
- Vaccine and Vaccination - Vaccines Congress-2025 (Canada)
- Vaccine Delivery Systems: Innovations and Challenges - Vaccines R&D 2026 (France)
- Vaccine Development for Cancer Immunotherapy - Vaccines R&D 2026 (France)
- Vaccine Development for Vector-Borne Diseases - Vaccines R&D 2026 (France)
- Vaccine efficiency and well-being - Vaccines Congress-2025 (Canada)
- Vaccine Equity and Access in Low-Resource Settings - Vaccines R&D 2026 (France)
- Vaccine for infectious illnesses in humans - Vaccines Congress-2025 (Canada)
- Vaccine Hesitancy and Public Perception - Vaccines R&D 2026 (France)
- Vaccine Manufacturing and Distribution - Vaccines R&D 2026 (France)
- Vaccine manufacturing technologies - Vaccines Congress-2025 (Canada)
- Vaccine Research and Clinical trials - Vaccines Congress-2025 (Canada)
- Vaccine Research Ethics and Regulations - VACCINE CONGRESS 2025 (Japan)
- Vaccine Safety and Pharmacovigilance - VACCINE CONGRESS 2025 (Japan)
- Vaccine Safety and Pharmacovigilance - Vaccines R&D 2026 (France)
- Vaccines against non-traditional illnesses - Vaccines Congress-2025 (Canada)
- VACCINES FOR CANCER - Vaccines Congress-2025 (Canada)
- Veterinary and Zoonotic Vaccines - VACCINE CONGRESS 2025 (Japan)
- Workshops and Poster Sessions - VACCINE CONGRESS 2025 (Japan)
- Zika Virus vaccines - Vaccines Congress-2025 (Canada)